Sperm separation is an integral part of IVF procedures used in both animal breeding and human assisted reproduction treatments. Cytoswim is developing single-use consumable lab chips for isolating the fittest sperm cells to maximise fertility. Our device improves the selection of the viable sperm by 2x compared to current methods.
Current sperm conditioning is achieved primarily through density gradient centrifugation which relies on both expensive separation reagents and an expensive and maintenance-intensive centrifuge. Alongside this there is growing evidence that this technique can damage the sample, reducing the likelihood of pregnancy compared to gentler separation.
Our single-use device relies on a proprietary microstructure to separate out the healthier and faster cells from a sample. It uses no power and is compatible with existing lab processes and reagents. In side-by-side comparisons, our device outperformed current standard separation procedures by >2x and significantly reduced the amount active technician time.
Gateway market in research mice: 10,000 IVF cycles performed for breeding of research mice each year in the UK alone, with a further 50,000 across Europe and 100,000 in US and Canada. Success rates for current procedures are often less than 10% so demand for improved procedures is high. Addressable market opportunity = £6M p.a.
Chair: Chris Sheehan
CEO & Founder: Dr Max Meissner